Emotion regulation allows people to influence and modify the intensity, duration and types of emotions experienced, and how these emotions are expressed. The capacity to regulate emotions increases and becomes more sophisticated throughout child development due to the maturation of prefrontal brain regions involved in executive functioning. Emotion regulation is a transdiagnostic process that plays a pivotal role in the development and maintenance of internalizing and externalizing symptoms such as anxiety, depression or problematic behaviors. Emotion dysregulation is a prominent feature of neurodevelopmental conditions such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Furthermore, emotion dysregulation has been suggested to play a vital role in less commonly diagnosed neurogenetic disorders such as Phelan-McDermid Syndrome, germline heterozygous PTEN mutations and 22q11.2 deletion syndrome. Fortunately, emotion regulation processes are amenable to treatment in various clinical and non-clinical populations.
Our goal is to bring together theoretical insights, methodological developments and novel empirical findings of emotion regulation in individuals diagnosed with neurodevelopmental disorders, including but not limited to ASD, ADHD and neurogenetic disorders. We include cutting-edge research on measurement development and mechanisms behind emotion regulation deficits. Furthermore, emphasis will be placed on treatment trials evaluating the effectiveness of different treatment modalities on a range of primary and secondary outcomes, including emotion regulation, emotion reactivity, psychopathology, behaviors, as well as identify factors that may influence treatment outcomes. A greater understanding of the factors associated with treatment outcomes across the lifespan is a necessary step towards providing more effective clinical care. Reviewing these studies together may give us insight into the transdiagnostic nature of emotion regulation across the various neurodevelopmental conditions. We anticipate that due to broad scope capturing topics from assessment, mechanisms to treatments, this collection of papers will be informative across both research and clinical contexts.
We welcome manuscripts on (but not limited to) the following topics:
• Developmental trajectories of emotion regulation in neurodevelopmental disorders
• Emotion regulation and comorbidities across the lifespan in neurodevelopmental disorders
• Innovations in and challenges associated with measuring emotion regulation
• Predictors of response to diverse treatment modalities
• Neuropsychological investigations, including cognitive markers of emotion dysregulation
• Neuroimaging studies (structural, functional, spectroscopy) of emotion regulation
• Novel treatment approaches and translational research
Emotion regulation allows people to influence and modify the intensity, duration and types of emotions experienced, and how these emotions are expressed. The capacity to regulate emotions increases and becomes more sophisticated throughout child development due to the maturation of prefrontal brain regions involved in executive functioning. Emotion regulation is a transdiagnostic process that plays a pivotal role in the development and maintenance of internalizing and externalizing symptoms such as anxiety, depression or problematic behaviors. Emotion dysregulation is a prominent feature of neurodevelopmental conditions such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). Furthermore, emotion dysregulation has been suggested to play a vital role in less commonly diagnosed neurogenetic disorders such as Phelan-McDermid Syndrome, germline heterozygous PTEN mutations and 22q11.2 deletion syndrome. Fortunately, emotion regulation processes are amenable to treatment in various clinical and non-clinical populations.
Our goal is to bring together theoretical insights, methodological developments and novel empirical findings of emotion regulation in individuals diagnosed with neurodevelopmental disorders, including but not limited to ASD, ADHD and neurogenetic disorders. We include cutting-edge research on measurement development and mechanisms behind emotion regulation deficits. Furthermore, emphasis will be placed on treatment trials evaluating the effectiveness of different treatment modalities on a range of primary and secondary outcomes, including emotion regulation, emotion reactivity, psychopathology, behaviors, as well as identify factors that may influence treatment outcomes. A greater understanding of the factors associated with treatment outcomes across the lifespan is a necessary step towards providing more effective clinical care. Reviewing these studies together may give us insight into the transdiagnostic nature of emotion regulation across the various neurodevelopmental conditions. We anticipate that due to broad scope capturing topics from assessment, mechanisms to treatments, this collection of papers will be informative across both research and clinical contexts.
We welcome manuscripts on (but not limited to) the following topics:
• Developmental trajectories of emotion regulation in neurodevelopmental disorders
• Emotion regulation and comorbidities across the lifespan in neurodevelopmental disorders
• Innovations in and challenges associated with measuring emotion regulation
• Predictors of response to diverse treatment modalities
• Neuropsychological investigations, including cognitive markers of emotion dysregulation
• Neuroimaging studies (structural, functional, spectroscopy) of emotion regulation
• Novel treatment approaches and translational research
